Episode Details

Revolution Medicines is poised to shake up the cancer drug market with its RAS-targeting drugs, especially daraxonrasib, which doubled survival rates in pancreatic cancer trials and could be worth over $10 billion. With another promising drug, zoldonrasib, in the pipeline and 30% of cancers linked to RAS, the company’s strategy targets a massive, untapped opportunity — though analysts caution that other stocks may offer higher growth potential right now.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/b95848a625a04b7b